EVAX Kapitalisasi Akuntansi evaxion-biotech.com

Evaxion Biotech A/S (EVAX) develops its AI algorithms using in-house personnel, while physical production and testing are fully outsourced to external contractors. The security of European law and the humanitarian profile of the projects minimize sanction risks, and the current indicator stands at 0.01. Historical price action confirms the success of the PIONEER and EDIVAX systems, which ensure leadership in the creation of personalized vaccines and allow for flexible management of service pricing.

EVAX Kapitalisasi Buku Evaxion Biotech A/S (04.07.2022 - 27.10.2026)

EVAX (Evaxion): rincian analitis lan laporan miturut indikator

- rega lan prakiraan konsensus rega:

Rega saham Evaxion Biotech AS|EVAX - Target konsensus

- data kapitalisasi pasar:

Kapitalisasi pasar Evaxion Biotech A/S|EVAX - Nilai Perusahaan

- data kapitalisasi buku:

Nilai Buku saben Saham Evaxion|EVAX - Kapitalisasi Buku|Kapitalisasi Pasar marang Nilai Buku evaxion-biotech.com|EVAX - Total Aset Perusahaan

- data utang lan likuiditas:

Utang marang Modal Evaxion Biotech A/S|EVAX - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas Evaxion Biotech|EVAX - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Evaxion Biotech A/S

Pambiji fundamental perusahaan:Evaxion Biotech A/S

To identify fundamental benchmarks within the financial statements of Evaxion Biotech A/S, it is critical for investors to track net asset dynamics to filter out market noise. By analyzing the trajectory of the company's book capitalization, one can assess the real growth of equity, which for this AI-biotech depends directly on the efficiency of reducing R&D costs while scaling the development of anti-cancer vaccines.

Pesaing utama